Johnson & Johnson Reports 2010 Second-Quarter Results:

Sales of $15.3 Billion Increased 0.6% Versus 2009 Second-Quarter; EPS was $1.23 Excluding Special Items, 2010 Second-Quarter EPS was $1.21, an increase of 5.2%*

NEW BRUNSWICK, N.J., July 20 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%.  Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.

Net earnings and diluted earnings per share for the second quarter of 2010 were $3.4 billion and $1.23, respectively. Second-quarter 2010 net earnings included an after-tax gain of $67 million representing the net impact of litigation matters. Excluding this special item, net earnings for the current quarter were $3.4 billion and diluted earnings per share were $1.21, representing increases of 5.4% and 5.2%, respectively, as compared to the same period in 2009.*

The Company updated its earnings guidance for full-year 2010 to $4.65 - $4.75 per share, which excludes the impact of special items. The Company's guidance now reflects the impact of the voluntary recalls announced earlier this year of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare facility in Fort Washington, Pa., as well as unfavorable changes in foreign currency exchange rates.

"Our second-quarter results include strong growth in a number of our recently launched products which contributed to solid earnings," said William C. Weldon, Chairman and Chief Executive Officer. "Remedial actions to address the product quality issues at McNeil Consumer Healthcare are ongoing and of high importance.  At the same time, we continue to make significant investments in acquisitions, strategic partnerships and in advancing our pipeline, positioning us well for future growth."

Worldwide Consumer sales of $3.6 billion for the second quarter represented a decrease of 5.4% versus the prior year consisting of an operational decline of 6.5% and a positive impact from currency of 1.1%. Domestic sales decreased 14.3%; international sales increased 1.8%, which reflected an operational decline of 0.2% and a positive currency impact of 2.0%.

Positive contributors to operational results were NEUTROGENA®, international sales of Baby Care products and JOHNSON'S® adult skin products.  These operational sales increases were more than offset by the impact of the previously announced recalls of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare Fort Washington, Pa., facility as well as the economic situation in Venezuela.

Worldwide Pharmaceutical sales of $5.6 billion for the second quarter represented an increase of 1.0% versus the prior year with operational growth of 1.0% with no impact from currency. Domestic sales decreased 2.0%; international sales increased 5.0%, which reflected an operational increase of 4.9% and a positive currency impact of 0.1%.  

Sales growth includes the strong performance of newly launched products including STELARA (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; SIMPONI (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; and INVEGA® SUSTENNA (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults.

Several other products had strong operational growth including PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; international sales of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment, an antipsychotic medication; and INTELENCE® (etravirine), a next generation non-nucleoside reverse transcriptase inhibitor for HIV.

Sales results of TOPAMAX® (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by continued generic competition.

During the quarter, the Company acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases.

Additionally the Company signed an exclusive agreement with Diamyd Medical AB to develop and commercialize the GAD65 antigen-based diabetes therapy.

Worldwide Medical Devices and Diagnostics sales of $6.1 billion for the second quarter represented an increase of 4.1% versus the prior year consisting of an operational increase of 3.5% and a positive currency impact of 0.6%. Domestic sales increased 3.2%; international sales increased 5.0%, which reflected an operational increase of 3.9% and a positive currency impact of 1.1%.

Primary contributors to operational growth included Ethicon's surgical care products; Ethicon Endo-Surgery's minimally invasive and advanced sterilization products; Biosense Webster's electrophysiology business; and DePuy's orthopaedic joint reconstruction business. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market.

During the quarter, the Company received clearance from the United States Food and Drug Administration to market narafilcon B, the first and only silicone hydrogel daily disposable contact lens in the United States, which will be marketed under the name 1-DAY ACUVUE®  TruEye Brand Contact Lenses.

In July, the Company entered into a definitive agreement to acquire Micrus Endovascular, a global developer and manufacturer of minimally invasive devices to address hemorrhagic and ischemic stroke. Also in July, Ethicon Endo-Surgery completed the divestiture of its Breast Care business to Devicor Medical Products, Inc.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items, such as the net impact of litigation gains, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measure can be found in the Investor Relations section of the Company's website at www.jnj.com.

NOTE TO INVESTORS

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections.  Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries 

Supplementary Sales Data


(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS






Percent Change






Percent Change


2010


2009


Total


Operations

Currency


2010


2009


Total


Operations

Currency

Sales to customers by




















segment of business








































Consumer




















   U.S.

$   1,463


1,708


(14.3)

%

(14.3)


-


$   3,023


3,434


(12.0)

%

(12.0)


-

   International

2,184


2,146


1.8


(0.2)


2.0


4,390


4,131


6.3


0.6


5.7


3,647


3,854


(5.4)


(6.5)


1.1


7,413


7,565


(2.0)


(5.1)


3.1





















Pharmaceutical




















   U.S.

3,110


3,172


(2.0)


(2.0)


-


6,316


6,846


(7.7)


(7.7)


-

   International

2,443


2,326


5.0


4.9


0.1


4,875


4,432


10.0


5.7


4.3


5,553


5,498


1.0


1.0


0.0


11,191


11,278


(0.8)


(2.5)


1.7





















Med Devices & Diagnostics




















   U.S.

2,865


2,776


3.2


3.2


-


5,751


5,428


6.0


6.0


-

   International

3,265


3,111


5.0


3.9


1.1


6,606


5,994


10.2


5.6


4.6


6,130


5,887


4.1


3.5


0.6


12,357


11,422


8.2


5.8


2.4





















U.S.

7,438


7,656


(2.8)


(2.8)


-


15,090


15,708


(3.9)


(3.9)


-

International

7,892


7,583


4.1


3.0


1.1


15,871


14,557


9.0


4.2


4.8

Worldwide

$ 15,330


15,239


0.6

%

0.1


0.5


$ 30,961


30,265


2.3

%

0.0


2.3



Johnson & Johnson and Subsidiaries

Supplementary Sales Data


(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS






Percent Change






Percent Change


2010


2009


Total


Operations

Currency


2010


2009


Total


Operations

Currency

Sales to customers by




















geographic area








































U.S.

$   7,438


7,656


(2.8)

%

(2.8)


-


$ 15,090


15,708


(3.9)

%

(3.9)


-





















Europe

3,832


3,972


(3.5)


1.3


(4.8)


7,934


7,643


3.8


2.9


0.9

Western Hemisphere excluding U.S.

1,375


1,215


13.2


2.6


10.6


2,655


2,277


16.6


3.1


13.5

Asia-Pacific, Africa

2,685


2,396


12.1


6.1


6.0


5,282


4,637


13.9


6.9


7.0

International

7,892


7,583


4.1


3.0


1.1


15,871


14,557


9.0


4.2


4.8





















Worldwide

$ 15,330


15,239


0.6

%

0.1


0.5


$ 30,961


30,265


2.3

%

0.0


2.3



Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings



(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER












2010


2009


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$ 15,330


100.0


$ 15,239


100.0


0.6

Cost of products sold

4,630


30.2


4,450


29.2


4.0

Selling, marketing and administrative expenses

4,756


31.0


4,797


31.5


(0.9)

Research expense

1,648


10.8


1,638


10.7


0.6

Interest (income)expense, net

58


0.4


85


0.6



Other (income)expense, net

18


0.1


6


-



Earnings before provision for taxes on income

4,220


27.5


4,263


28.0


(1.0)

Provision for taxes on income

771


5.0


1,055


6.9


(26.9)

Net earnings

$   3,449


22.5


$   3,208


21.1


7.5











Net earnings per share  (Diluted)

$     1.23




$     1.15




7.0











Average shares outstanding  (Diluted)

2,796.0




2,782.0















Effective tax rate

18.3

%


24.7

%













Adjusted earnings before provision for taxes and net earnings

    Earnings before provision for taxes on income

$   4,377

(1)

28.6


$   4,263


28.0


2.7

    Net earnings

$   3,382

(1)

22.1


$   3,208


21.1


5.4

    Net earnings per share  (Diluted)

$     1.21

(1)



$     1.15




5.2

    Effective tax rate

22.7

%



24.7

%














(1) The difference between as reported and as adjusted earnings is the exclusion of second quarter net litigation.  The impact of second quarter

    net litigation is $157 million expense on earnings before provision for taxes on income, $67 million income on net earnings and $0.02 per share on

    net earnings per share (diluted).



Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings


(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS












2010


2009


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$ 30,961


100.0


$ 30,265


100.0


2.3

Cost of products sold

9,158


29.6


8,701


28.7


5.3

Selling, marketing and administrative expenses

9,535


30.8


9,405


31.1


1.4

Research expense

3,205


10.4


3,156


10.4


1.6

Interest (income)expense, net

139


0.4


166


0.6



Other (income)expense, net

(1,576)


(5.1)


(69)


(0.2)



Earnings before provision for taxes on income

10,500


33.9


8,906


29.4


17.9

Provision for taxes on income

2,525


8.1


2,191


7.2


15.2

Net earnings

$   7,975


25.8


$   6,715


22.2


18.8











Net earnings per share  (Diluted)

$     2.85




$     2.41




18.3











Average shares outstanding  (Diluted)

2,796.1




2,785.5















Effective tax rate

24.0

%


24.6

%













Adjusted earnings before provision for taxes and net earnings 

    Earnings before provision for taxes on income

$   9,160

(1)

29.6


$   8,906


29.4


2.9

    Net earnings

$   6,998

(1)

22.6


$   6,715


22.2


4.2

    Net earnings per share  (Diluted)

$     2.50

(1)



$     2.41




3.7

    Effective tax rate

23.6

%



24.6

%














(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per

    share (diluted) is the exclusion of income from net litigation of $1,340 million, $977 million and $0.35 per share, respectively.




REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS




% Change




% Change


2010

2009

Reported

Operational (1)

Currency


2010

2009

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2)












SKIN CARE












US

422

411

2.7%

2.7%

-


874

834

4.8%

4.8%

-

Intl

421

422

-0.2%

-0.5%

0.3%


889

841

5.7%

0.9%

4.8%

WW

843

833

1.2%

1.1%

0.1%


1,763

1,675

5.3%

2.9%

2.4%

BABY CARE












US

99

104

-4.8%

-4.8%

-


202

206

-1.9%

-1.9%

-

Intl

438

404

8.4%

4.9%

3.5%


864

791

9.2%

3.1%

6.1%

WW

537

508

5.7%

2.9%

2.8%


1,066

997

6.9%

2.1%

4.8%

ORAL CARE












US

148

174

-14.9%

-14.9%

-


322

362

-11.0%

-11.0%

-

Intl

224

212

5.7%

1.8%

3.9%


431

389

10.8%

3.3%

7.5%

WW

372

386

-3.6%

-5.8%

2.2%


753

751

0.3%

-3.6%

3.9%

OTC/NUTRITIONALS












US

492

679

-27.5%

-27.5%

-


1,034

1,405

-26.4%

-26.4%

-

Intl

649

631

2.9%

1.9%

1.0%


1,314

1,253

4.9%

-0.5%

5.4%

WW

1,141

1,310

-12.9%

-13.4%

0.5%


2,348

2,658

-11.7%

-14.3%

2.6%

WOMEN'S HEALTH












US

137

152

-9.9%

-9.9%

-


283

301

-6.0%

-6.0%

-

Intl

329

329

0.0%

-2.1%

2.1%


652

603

8.1%

2.4%

5.7%

WW

466

481

-3.1%

-4.5%

1.4%


935

904

3.4%

-0.4%

3.8%

WOUND CARE / OTHER












US

165

188

-12.2%

-12.2%

-


308

326

-5.5%

-5.5%

-

Intl

123

148

-16.9%

-20.3%

3.4%


240

254

-5.5%

-11.4%

5.9%

WW

288

336

-14.3%

-15.8%

1.5%


548

580

-5.5%

-8.1%

2.6%

TOTAL CONSUMER












US

1,463

1,708

-14.3%

-14.3%

-


3,023

3,434

-12.0%

-12.0%

-

Intl

2,184

2,146

1.8%

-0.2%

2.0%


4,390

4,131

6.3%

0.6%

5.7%

WW

3,647

3,854

-5.4%

-6.5%

1.1%


7,413

7,565

-2.0%

-5.1%

3.1%

























* See footnotes below



PHARMACEUTICAL SEGMENT  (2) (6)

ACIPHEX/PARIET












US

121

128

-5.5%

-5.5%

-


240

266

-9.8%

-9.8%

-

Intl

133

132

0.8%

2.1%

-1.3%


274

257

6.6%

2.7%

3.9%

WW

254

260

-2.3%

-1.6%

-0.7%


514

523

-1.7%

-3.6%

1.9%

CONCERTA












US

223

233

-4.3%

-4.3%

-


454

502

-9.6%

-9.6%

-

Intl

100

84

19.0%

16.3%

2.7%


198

159

24.5%

16.7%

7.8%

WW

323

317

1.9%

1.2%

0.7%


652

661

-1.4%

-3.3%

1.9%

DURAGESIC/FENTANYL TRANSDERMAL












US

37

50

-26.0%

-26.0%

-


75

125

-40.0%

-40.0%

-

Intl

147

168

-12.5%

-12.6%

0.1%


293

324

-9.6%

-13.1%

3.5%

WW

184

218

-15.6%

-15.7%

0.1%


368

449

-18.0%

-20.5%

2.5%

LEVAQUIN/FLOXIN












US

289

343

-15.7%

-15.7%

-


652

751

-13.2%

-13.2%

-

Intl

11

19

-42.1%

-44.8%

2.7%


19

36

-47.2%

-50.2%

3.0%

WW

300

362

-17.1%

-17.2%

0.1%


671

787

-14.7%

-14.8%

0.1%

PREZISTA












US

99

65

52.3%

52.3%

-


188

137

37.2%

37.2%

-

Intl

105

75

40.0%

42.1%

-2.1%


203

125

62.4%

57.3%

5.1%

WW

204

140

45.7%

46.8%

-1.1%


391

262

49.2%

46.8%

2.4%

PROCRIT/EPREX












US

306

330

-7.3%

-7.3%

-


596

651

-8.4%

-8.4%

-

Intl

220

247

-10.9%

-9.3%

-1.6%


453

476

-4.8%

-7.8%

3.0%

WW

526

577

-8.8%

-8.1%

-0.7%


1,049

1,127

-6.9%

-8.2%

1.3%

REMICADE












US

783

771

1.6%

1.6%

-


1,563

1,508

3.6%

3.6%

-

US Exports (3)

341

327

4.3%

4.3%

-


741

613

20.9%

20.9%

-

Intl

6

4

50.0%

50.0%

-


12

9

33.3%

33.2%

0.1%

WW

1,130

1,102

2.5%

2.5%

-


2,316

2,130

8.7%

8.7%

-

RISPERDAL/RISPERIDONE












US

(17)

70

-124.3%

-124.3%

-


(12)

188

-106.4%

-106.4%

-

Intl

134

169

-20.7%

-22.1%

1.4%


267

326

-18.1%

-21.2%

3.1%

WW

117

239

-51.0%

-52.0%

1.0%


255

514

-50.4%

-52.4%

2.0%

RISPERDAL CONSTA












US

115

131

-12.2%

-12.2%

-


232

257

-9.7%

-9.7%

-

Intl

240

217

10.6%

12.8%

-2.2%


502

416

20.7%

16.9%

3.8%

WW

355

348

2.0%

3.4%

-1.4%


734

673

9.1%

6.8%

2.3%

TOPAMAX












US

59

75

-21.3%

-21.3%

-


116

570

-79.6%

-79.6%

-

Intl

83

107

-22.4%

-21.4%

-1.0%


174

214

-18.7%

-21.6%

2.9%

WW

142

182

-22.0%

-21.4%

-0.6%


290

784

-63.0%

-63.8%

0.8%

VELCADE












US

-

-

-

-

-


-

-

0.0%

0.0%

-

Intl

286

229

24.9%

25.1%

-0.2%


547

421

29.9%

25.8%

4.1%

WW

286

229

24.9%

25.1%

-0.2%


547

421

29.9%

25.8%

4.1%

OTHER












US

754

649

16.2%

16.2%

-


1,471

1,278

15.1%

15.1%

-

Intl

978

875

11.8%

10.3%

1.5%


1,933

1,669

15.8%

10.5%

5.3%

WW

1,732

1,524

13.6%

12.8%

0.8%


3,404

2,947

15.5%

12.5%

3.0%

TOTAL PHARMACEUTICAL












US

3,110

3,172

-2.0%

-2.0%

-


6,316

6,846

-7.7%

-7.7%

-

Intl

2,443

2,326

5.0%

4.9%

0.1%


4,875

4,432

10.0%

5.7%

4.3%

WW

5,553

5,498

1.0%

1.0%

0.0%


11,191

11,278

-0.8%

-2.5%

1.7%

MAJOR NEW PHARM PRODUCTS (4)












INVEGA












US

68

67

1.5%

1.5%

-


137

133

3.0%

3.0%

-

Intl

34

32

6.3%

8.3%

-2.0%


73

57

28.1%

23.8%

4.3%

WW

102

99

3.0%

3.6%

-0.6%


210

190

10.5%

9.2%

1.3%













* See footnotes below

MEDICAL DEVICES AND DIAGNOSTICS   (2)

CORDIS (5)












US

265

252

5.2%

5.2%

-


516

498

3.6%

3.6%

-

Intl

390

422

-7.6%

-8.6%

1.0%


811

844

-3.9%

-7.4%

3.5%

WW

655

674

-2.8%

-3.4%

0.6%


1,327

1,342

-1.1%

-3.3%

2.2%

DEPUY












US

776

762

1.8%

1.8%

-


1,590

1,528

4.1%

4.1%

-

Intl

599

561

6.8%

6.0%

0.8%


1,239

1,087

14.0%

8.5%

5.5%

WW

1,375

1,323

3.9%

3.5%

0.4%


2,829

2,615

8.2%

5.9%

2.3%

DIABETES CARE












US

313

306

2.3%

2.3%

-


603

576

4.7%

4.7%

-

Intl

303

304

-0.3%

1.1%

-1.4%


610

575

6.1%

3.2%

2.9%

WW

616

610

1.0%

1.7%

-0.7%


1,213

1,151

5.4%

4.0%

1.4%

ETHICON












US

509

452

12.6%

12.6%

-


1,019

857

18.9%

18.9%

-

Intl

623

589

5.8%

5.0%

0.8%


1,260

1,137

10.8%

6.1%

4.7%

WW

1,132

1,041

8.7%

8.2%

0.5%


2,279

1,994

14.3%

11.6%

2.7%

ETHICON ENDO-SURGERY












US

507

489

3.7%

3.7%

-


990

943

5.0%

5.0%

-

Intl

689

626

10.1%

8.8%

1.3%


1,374

1,187

15.8%

10.7%

5.1%

WW

1,196

1,115

7.3%

6.6%

0.7%


2,364

2,130

11.0%

8.2%

2.8%

ORTHO-CLINICAL DIAGNOSTICS












US

264

284

-7.0%

-7.0%

-


552

561

-1.6%

-1.6%

-

Intl

230

210

9.5%

8.4%

1.1%


467

400

16.8%

12.2%

4.6%

WW

494

494

0.0%

-0.5%

0.5%


1,019

961

6.0%

4.1%

1.9%

VISION CARE












US

232

231

0.4%

0.4%

-


481

465

3.4%

3.4%

-

Intl

430

399

7.8%

3.9%

3.9%


845

764

10.6%

5.4%

5.2%

WW

662

630

5.1%

2.6%

2.5%


1,326

1,229

7.9%

4.6%

3.3%

TOTAL MEDICAL DEVICES AND DIAGNOSTICS












US

2,865

2,776

3.2%

3.2%

-


5,751

5,428

6.0%

6.0%

-

Intl

3,265

3,111

5.0%

3.9%

1.1%


6,606

5,994

10.2%

5.6%

4.6%

WW

6,130

5,887

4.1%

3.5%

0.6%


12,357

11,422

8.2%

5.8%

2.4%













(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported in U.S. sales

(4) Included in Other

(5) Includes sales of Drug-Eluting Stents for Q2 2010 of $59, $108 and $167MM Domestic, International and Worldwide respectively  

    Includes sales of Drug-Eluting Stents for Q2 2009 of $69, $165 and $234MM Domestic, International and Worldwide respectively

    Includes sales of Drug-Eluting Stents for June YTD 2010 of $119, $238 and $357MM Domestic, International and Worldwide respectively

    Includes sales of Drug-Eluting Stents for June YTD 2009 of $136, $349 and $485MM Domestic, International and Worldwide respectively

(6) Conforms to current presentation



SOURCE Johnson & Johnson

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.